Michael Robin Witt
Directeur Général chez GABATHER AB
Postes actifs de Michael Robin Witt
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| GABATHER AB | Directeur/Membre du Conseil | 01/09/2014 | - |
| Directeur Général | 01/10/2018 | - | |
| Investor Relations Contact | - | - | |
| Lead Discovery Malaysia Sdn. Bhd. | Directeur Général | 01/01/2012 | - |
| Directeur Technique/Scientifique/R&D | 01/01/2012 | - |
Historique de carrière de Michael Robin Witt
Anciens postes connus de Michael Robin Witt
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Axcentua Pharmaceuticals AB
 Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | Directeur Technique/Scientifique/R&D | 01/09/2010 | 01/04/2012 |
| Fondateur | 01/01/2007 | 01/04/2012 | |
| KARO PHARMA AB (PUBL) | Directeur Technique/Scientifique/R&D | 01/01/2002 | - |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Corporate Officer/Principal | - | - |
| NTG NORDIC TRANSPORT GROUP A/S | Corporate Officer/Principal | - | - |
Formation de Michael Robin Witt
| Vrije Universiteit Brussel | Doctorate Degree |
| Danmarks Farmaceutiske Universitet | Doctorate Degree |
Statistiques
Internationale
| Suède | 5 |
| Danemark | 3 |
| Belgique | 2 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 3 |
| Doctorate Degree | 2 |
| Corporate Officer/Principal | 2 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
| Transportation | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| KARO PHARMA AB (PUBL) | Health Technology |
| NTG NORDIC TRANSPORT GROUP A/S | Transportation |
| GABATHER AB | Health Technology |
| Entreprise privées | 3 |
|---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
Axcentua Pharmaceuticals AB
Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | Health Technology |
| Lead Discovery Malaysia Sdn. Bhd. |
- Bourse
- Insiders
- Michael Robin Witt
- Expérience
